![Jens W. Kindtler](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Profil
Jens W.
Kindtler served as Chairman at F2G Ltd. He was a Director at Resistentia Pharmaceuticals AB from 2003 to 2010.
He also served as a Director at Zealand Pharma A, Thrombologic ApS, and as a Non-Executive Director at Smartbead Technologies Ltd. and Pronostics Ltd. Prior to that, he was a Partner at BI Technology A from 2001 to 2009.
Mr. Kindtler graduated from the Technical University of Denmark with a graduate degree and earned an MBA from Henley Management College.
Anciens postes connus de Jens W. Kindtler
| Sociétés | Poste | Fin |
|---|---|---|
Thrombologic ApS
 Thrombologic ApS Miscellaneous Commercial ServicesCommercial Services Provides medical research and develops therapeutics | Directeur/Membre du Conseil | 20/03/2014 |
Resistentia Pharmaceuticals AB
 Resistentia Pharmaceuticals AB Pharmaceuticals: MajorHealth Technology Develops immunotherapy products | Directeur/Membre du Conseil | 24/06/2010 |
BI Technology A/S
 BI Technology A/S Investment ManagersFinance BI-T is an active venture capital investment manager following a hands-on approach and investing primarily in high-growth life science technology companies with global expansion potential. Investment criteria include an experienced management team, an innovative business concept with a competitive edge based on proven distinctive technology, a clearly defined medical need and patient population, and adequate IP protection by a strong patent portfolio. The firm focuses on unlisted, research-based biotechnology companies dedicated to developing profitable pharmaceuticals for the treatment of human diseases. They pay attention to unmet medical needs, potential medical improvements and major markets. They favor companies with advanced R&D supporting a market launch in the foreseeable future. They invest primarily in Europe, particularly in Denmark and the Nordic countries, and occasionally in the US where they co-invest with third parties. BI-T also invests in the energy technology field, focusing on renewable energy, energy storage, conversion and distribution as well as on improvements to the traditional energy sector. They aim to support the profitable development of sustainable and environmentally-clean alternative energies such as wind, water and solar power as well as clean fuels such as natural gas, hydrogen and biofuels. They invest in Denmark and Europe through direct equity participations in share increases, and target companies with attractive exit potential. They favor startups and early-expansion-stage companies with a credible business model based on proprietary products or services. BI-T provides intensive advisory and consultancy services to their portfolio companies. They follow up their initial investment with additional capital. The firm exits their investments through IPOs and trade sales, and their targeted exit horizon is three to ten years. Finally, the firm is involved in private equity investing in emerging markets in Africa and Asia, particularly in Vietnam, South Africa, East Africa and Egypt. Their investments are often supported by DANIDA-Danish International Development Assistance grants. Investments in Southeast Asia are managed out of a representative office in Ho Chi Minh City, Vietnam. | Private Equity Investor | 01/02/2009 |
Smartbead Technologies Ltd.
 Smartbead Technologies Ltd. Medical DistributorsDistribution Services Provides drug development and research services | Directeur/Membre du Conseil | 01/07/2006 |
| ZEALAND PHARMA A/S | Directeur/Membre du Conseil | - |
Formation de Jens W. Kindtler
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
22
Relations au 1er degré
9
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 9 |
|---|---|
Resistentia Pharmaceuticals AB
Resistentia Pharmaceuticals AB Pharmaceuticals: MajorHealth Technology Develops immunotherapy products | Health Technology |
BI Technology A/S
BI Technology A/S Investment ManagersFinance BI-T is an active venture capital investment manager following a hands-on approach and investing primarily in high-growth life science technology companies with global expansion potential. Investment criteria include an experienced management team, an innovative business concept with a competitive edge based on proven distinctive technology, a clearly defined medical need and patient population, and adequate IP protection by a strong patent portfolio. The firm focuses on unlisted, research-based biotechnology companies dedicated to developing profitable pharmaceuticals for the treatment of human diseases. They pay attention to unmet medical needs, potential medical improvements and major markets. They favor companies with advanced R&D supporting a market launch in the foreseeable future. They invest primarily in Europe, particularly in Denmark and the Nordic countries, and occasionally in the US where they co-invest with third parties. BI-T also invests in the energy technology field, focusing on renewable energy, energy storage, conversion and distribution as well as on improvements to the traditional energy sector. They aim to support the profitable development of sustainable and environmentally-clean alternative energies such as wind, water and solar power as well as clean fuels such as natural gas, hydrogen and biofuels. They invest in Denmark and Europe through direct equity participations in share increases, and target companies with attractive exit potential. They favor startups and early-expansion-stage companies with a credible business model based on proprietary products or services. BI-T provides intensive advisory and consultancy services to their portfolio companies. They follow up their initial investment with additional capital. The firm exits their investments through IPOs and trade sales, and their targeted exit horizon is three to ten years. Finally, the firm is involved in private equity investing in emerging markets in Africa and Asia, particularly in Vietnam, South Africa, East Africa and Egypt. Their investments are often supported by DANIDA-Danish International Development Assistance grants. Investments in Southeast Asia are managed out of a representative office in Ho Chi Minh City, Vietnam. | Finance |
Zealand Pharma A/S
 Zealand Pharma A/S BiotechnologyHealth Technology Operates as a biotechnology company that discovers and develops peptide based medicines | Health Technology |
Technical University of Denmark
 Technical University of Denmark Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Smartbead Technologies Ltd.
Smartbead Technologies Ltd. Medical DistributorsDistribution Services Provides drug development and research services | Distribution Services |
Henley Management College
 Henley Management College Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Pronostics Ltd.
 Pronostics Ltd. Pharmaceuticals: MajorHealth Technology Provides and develops diagnostic test for heart disease | Health Technology |
F2G Ltd.
 F2G Ltd. Pharmaceuticals: MajorHealth Technology Engages in research and development of novel drugs for life-threatening systemic fungal diseases treatment | Health Technology |
Thrombologic ApS
Thrombologic ApS Miscellaneous Commercial ServicesCommercial Services Provides medical research and develops therapeutics | Commercial Services |
